Maxime Verhoeven

52 Chapter 3 REFERENCES 1. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76 , 960–977 (2017). 2. Strehl, C. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann. Rheum. Dis. 75 , 952–957 (2016). 3. Hoes, J. N., Jacobs, J. W. G., Verstappen, S. M. M., Bijlsma, J. W. J. & van der Heijden, G. J. M. G. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta- analysis. Ann. Rheum. Dis. 68 , 1833–1838 (2009). 4. Caldwell, J. R. & Furst, D. E. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin. Arthritis Rheum. 21 , 1–11 (1991). 5. Buttgereit, F., Burmester, G. R., Straub, R. H., Seibel, M. J. & Zhou, H. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 63 , 1–9 (2011). 6. Bakker, M. F. et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156 , 329–338 (2012). 7. Goekoop-Ruiterman, Y. P. M. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52 , 3381–3390 (2005). 8. Landewé, R. B. M. et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum. 46 , 347–356 (2002). 9. Ajeganova, S. & Huizinga, T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther. Adv. Musculoskelet. Dis. 9 , 249–262 (2017). 10. Lequerré, T., Rottenberg, P., Derambure, C., Cosette, P. & Vittecoq, O. Predictors of treatment response in rheumatoid arthritis. Jt. Bone Spine 86 , 151–158 (2019). 11. Raza, K. & Filer, A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close ? Ann. Rheum. Dis. 74 , 793–794 (2015). 12. Bijlsma, J. W. J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 , 343–355 (2016). 13. Smolen, J. S. & Aletaha, D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 63 , 43–52 (2011). 14. Boers, M. et al. A new graph and scoring system simplified analysis of changing states: disease remissions in a rheumatoid arthritis clinical trial. J. Clin. Epidemiol. 63 , 633–637 (2010). 15. Genovese, M. C. et al. Transaminase levels and hepatic events during tocilizumab treatment pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol. 69 , 1751–1761 (2017). 16. Cole, T. J. & Altman, D. G. Statistics Notes: percentage differences, symmetry, and natural logarithms. BMJ 358 , 1–2 (2017). 17. Marshall, A., Altman, D. G., Holder, R. L. & Royston, P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med. Res. Methodol. 9 , 57 (2009). 18. Schoels, M., Alasti, F., Smolen, J. S. & Aletaha, D. Evaluation of newly proposed remission cut- points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res. Ther. 19 , 155 (2017).